The approval was backed by Abbott’s Distinct study, which is the largest randomized controlled trial for spinal cord stimulation in chronic back pain patients who are ineligible for surgery, according to a news release. The study followed 270 patients and found that 91.4 percent of those recieving spinal cord stimulation saw significant pain relief or improved function.
The indication will span across Abbott’s entire spinal cord stimulator portfolio including the recharge-free Proclaim and rechargable Eterna.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
